Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2025 | Examining the role of liquid biopsy in renal cell carcinoma

Chinmay Jani • 14 Feb 2025
GU Cancers 2025
Genitourinary Cancer Kidney Cancer

Chinmay Jani, MBBS, Sylvester Comprehensive Cancer Center, Doral, FL, describes a review on the evolving role of liquid biopsy in cancer diagnostics, prognostics, and treatment decision-making in renal cell carcinoma (RCC). Dr Jani highlights the potential of various liquid biopsy components, including circulating tumor DNA (ctDNA), cell-free DNA, and circulating tumor RNA (ctRNA), in detecting novel alterations and guiding personalized treatment approaches. By analyzing multiple studies, this review provides a narrative overview of current advancements and emerging platforms in liquid biopsy. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Chinmay Jani

AI tools for clinical advice in NSCLC without actionable mutations
2:16
AI tools for clinical advice in NSCLC without actionable mutations
Chinmay Jani • 16 Sep 2026
Younger patients with lung cancer show distinct genomic and immune phenotype alterations
3:10
Younger patients with lung cancer show distinct genomic and immune phenotype alterations
Chinmay Jani • 16 Sep 2026
Actionable alterations and targeted therapies in younger patients with lung cancer
1:16
Actionable alterations and targeted therapies in younger patients with lung cancer
Chinmay Jani • 16 Sep 2026
ctDNA and ctRNA for the detection of actionable fusions in NSCLC
2:10
ctDNA and ctRNA for the detection of actionable fusions in NSCLC
Chinmay Jani • 16 Sep 2026

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals